First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
MOLECULAR CANCER THERAPEUTICS（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要